


Company Registration No. 4465622

**Abingworth Bioventures IIA GP
Limited**

Report and Financial Statements

30 June 2013



Abingworth Bioventures IIA GP Limited

Report and financial statements 2013

Contents	Page
Officers and professional advisers	1
Directors' report	2
Statements of directors' responsibilities	4
Independent auditor's report	5
Profit and loss account	7
Balance sheet	8
Notes to the accounts	9

Abingworth Bioventures IIA GP Limited

Report and financial statements 2013

Officers and professional advisers

Directors

S W Bunting
J F Abell
D F J Leathers

Secretary

J G Heard

Registered office

38 Jermyn Street
London
SW1Y 6DN

Banker

Barclays Bank PLC
Pall Mall Corporate Group
London
SW1A 1QB

Auditor

Deloitte LLP
London

Tax Consultant

BDO Stoy Hayward LLP
Chartered Accountants
London & New York

Abingworth Bioventures IIA GP Limited

Directors' report

The directors present their annual report and the audited financial statements for the year ended 30 June 2013. This directors' report has been prepared in accordance with the provisions applicable to companies entitled to the small companies' exemption.

Principal activities

Abingworth Bioventures IIA GP Limited (the "Company") acts as the general partner of a Scottish limited partnership, Abingworth Bioventures IIA LP (the "Fund").

Business review

The Company made a profit after taxation of £3,239 (2012: profit of £3,164). The directors consider the results satisfactory.

Going Concern

The directors expect that both the Abingworth Bioventures IIA LP and the Company will cease to operate in the next financial year. As required by FRS 18 Accounting Policies, the directors have prepared the financial statements on the basis that the company is no longer a going concern. No material adjustments arise as a result of ceasing to apply the going concern basis.

Financial risk management

The Company does not use any derivative financial instruments or debt finance and as the major costs are met by the holding company, there is minimal cash flow risk and liquidity risk.

Dividends

The directors do not recommend a dividend payment (2012: £nil).

Indemnity

The directors have been covered by liability insurance throughout the year and the policy of insurance remains in force.

Future prospects

The Fund sold its last investment in July 2013 and accordingly both the Company and the Fund are expected to be wound up during the next financial year.

Directors

The directors of Abingworth Bioventures IIA GP Limited who served throughout the year and to the date of this report are:

S W Bunting
J F Abell
D F J Leathers

Abingworth Bioventures IIA GP Limited

Directors' report (continued)

Disclosure of information to auditor

Each of the persons who is a director at the date of approval of this report confirms that


- 1 so far as the director is aware, there is no relevant audit information of which the Company's auditor is unaware, and
- 2 the director has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the Company's auditor is aware of that information

This confirmation is given and should be interpreted in accordance with the provisions of s418 of the Companies Act 2006

Auditor

A resolution to re-appoint Deloitte LLP as the company's auditor will be proposed at the forthcoming Annual General Meeting

Approved by the Board of Directors
and signed on behalf of the Board



J G Heard
Secretary

17 October 2013

Abingworth Bioventures IIA GP Limited

Statement of directors' responsibilities

The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period. In preparing these financial statements, the directors are required to

- select suitable accounting policies and then apply them consistently,
- make judgements and accounting estimates that are reasonable and prudent,
- state whether applicable UK Accounting Standards have been followed, and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Independent auditor's report to the members of Abingworth Bioventures IIA GP Limited

We have audited the financial statements of Abingworth Bioventures IIA GP Limited for the year ended 30 June 2013 which comprise the Profit and Loss Account, the Balance Sheet and the related notes 1 to 13. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

This report is made solely to the Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of directors and auditor

As explained more fully in the statement of directors' responsibilities, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view. Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

Scope of the audit of the financial statements

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of whether the accounting policies are appropriate to the Company's circumstances and have been consistently applied and adequately disclosed, the reasonableness of significant accounting estimates made by the directors, and the overall presentation of the financial statements. In addition, we read all the financial and non-financial information in the annual report to identify material inconsistencies with the audited financial statements. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report.

Emphasis of matter – Financial statements prepared other than on a going concern basis

In forming our opinion on the financial statements, which is not modified, we have considered the adequacy of the disclosure made in note 1 to the financial statements, which explains that the financial statements have been prepared on a basis other than that of a going concern.

Opinion on financial statements

In our opinion the financial statements

- give a true and fair view of the state of the company's affairs as at 30 June 2013 and of its profit for the year then ended,
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice, and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Independent auditor's report to the members of Abingworth Bioventures IIA GP Limited (continued)

Opinion on other matter prescribed by the Companies Act 2006

In forming our opinion on the financial statements, which is not modified, we have considered the adequacy of the disclosure made in note 1 to the financial statements, which explains that the financial statements have been prepared on a basis other than that of a going concern

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us, or
- the financial statements are not in agreement with the accounting records and returns, or
- certain disclosures of directors' remuneration specified by law are not made, or
- we have not received all the information and explanations we require for our audit, or
- the directors were not entitled to take advantage of the small companies exemption in preparing the directors' report



Brian Forrester (Senior Statutory Auditor)
for and on behalf of Deloitte LLP
Chartered Accountants and Statutory Auditor
London, United Kingdom

17 October 2013

Abingworth Bioventures IIA GP Limited

Profit and loss account Year ended 30 June 2013

	Notes	2013 £	2012 £
Turnover	2	3,126	3,185
Administrative income		692	270
Profit on ordinary activities before taxation	3	3,818	3,455
Tax charge on ordinary activities	6	(579)	(291)
Profit on ordinary activities after taxation	10, 11	3,239	3,164

All results relate to continuing operations. There have been no recognised gains or losses other than as stated in the profit and loss account for the current or prior year. Accordingly, no statement of total recognised gains and losses is given.

The notes 1 to 13 form an integral part of the accounts.

Abingworth Bioventures IIA GP Limited


Balance sheet 30 June 2013

	Notes	2013 £	2012 £
Fixed assets			
Investments	4	1	1
Current assets			
Cash at bank and in hand		23,213	19,469
Total current assets		23,213	19,469
Creditors: amounts falling due within one year			
Other creditors	5	(7,858)	(74)
Net current assets		15,355	19,395
Total assets less current liabilities		15,356	19,396
Provision for liabilities and charges	7	-	(7,279)
Net assets		15,356	12,117
Capital and reserves			
Called up share capital	9	1	1
Profit and loss account	10	15,355	12,116
Total equity shareholders' funds	11	15,356	12,117

The notes 1 to 13 form an integral part of the accounts

These financial statements (company registration number 4465622) were approved by the Board of Directors and authorised for issue on 17 October 2013

Signed on behalf of the Board of Directors



J F Abell
Director

Abingworth Bioventures IIA GP Limited

Notes to the accounts Year ended 30 June 2013

1. Accounting policies

The financial statements are prepared in accordance with applicable United Kingdom law and accounting standards. The particular accounting policies adopted are described below and have been consistently adopted in the current and prior years.

Accounting convention

The financial statements are prepared under the historical cost convention.

Going concern

The Company's business, together with the factors likely to affect the future development, performance and position are set out on page 2 of the Directors' Report. As stated in the Directors' report, the directors expect that both the Abingworth Bioventures IIA LP and the Company will cease to operate in the next financial year. No material adjustments arise as a result of ceasing to apply the going concern basis, other than a presentation change of all long term provisions and liabilities moved to creditors falling due within one year (see note 7).

Turnover

Turnover comprises the Company's share of profits made by Abingworth Bioventures IIA LP.

Abingworth Bioventures IIA GP Limited is the general partner of Abingworth Bioventures IIA LP (the "Fund"). Under the Fund's limited partnership agreement, Abingworth Bioventures IIA GP Limited is entitled to receive a "General Partner's Share". The General Partner's Share comprises the first charge on net income and capital gains of the Fund, an annual profit share equivalent to a fixed amount of \$5,000. If net income and capital gains less capital losses in any accounting period are less than the General Partner's Share, the deficiency is paid as an interest free loan, which is recoverable only against future allocations of net income and capital gains. As these advances are not repayable under the terms of the limited partnership agreement, the advances are recognised as turnover as they are earned.

Investments

Investments held as fixed assets are stated at cost less provision for any impairment in value.

Cash flow statement

The Company has taken advantage of the exemption granted within Financial Reporting Standard 1 (Revised) Cash Flow Statements not to prepare a cash flow statement as its ultimate parent company produces consolidated accounts, which include a cash flow statement, which are publicly available, and into which the Company's results are fully consolidated.

Taxation

The charge for taxation is based on the profit for the period and takes into account deferred taxation that arises because of timing differences between the treatments of certain items for taxation and accounting purposes.

Current tax is provided at amounts expected to be paid (or received) using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred taxation is provided in full on timing differences that result in an obligation at the balance sheet date to pay more tax, or a right to pay less tax, at a future date, at rates expected to apply when they crystallise based on current tax rates and law. Timing differences arise from the inclusion of items of income and expenditure in taxation computations in periods different from those in which they are included in financial statements. Deferred tax assets are recognised to the extent that it is regarded as more likely than not that they will be recovered. Deferred tax assets and liabilities are not discounted.

Abingworth Bioventures IIA GP Limited

Notes to the accounts Year ended 30 June 2013

1. Accounting policies (continued)

Foreign exchange

Transactions denominated in foreign currencies are translated into sterling at the rates ruling at the dates of the transactions or at a contracted rate, if appropriate

Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are translated at the rates ruling at that date. All translation differences are recognised in the profit and loss account for the period

2. Turnover

In the opinion of the directors, the Company activities as described in the Directors' Report can be regarded as a single business segment

In addition, the Company operated in the United Kingdom which in the opinion of the directors can be regarded as a single geographical market

3. Profit on ordinary activities before taxation

	2013	2012
	£	£
Profit on ordinary activities before taxation is stated after charging		
Auditor's remuneration - audit of the company	-	-
Foreign currency exchange gains	719	299
	<u>719</u>	<u>299</u>

The Company had no employees in either year. The three directors did not receive any remuneration during either year for their services to this company. Abingworth Management Holdings Limited, the parent company, meets the audit fee for the Company of £6,000 (2012: £5,252)

4. Investments

	Interests in partnerships £
At cost and net book value:	
As at 30 June 2012 and 30 June 2013	<u>1</u>

The investment relates to a non equity interest in Abingworth Bioventures IIA L P, a limited partnership registered in England and Wales, whose principal place of business is the United Kingdom. Abingworth Bioventures IIA L P invests in companies in Life Sciences, Biotechnology and related areas in Europe and North America

Abingworth Bioventures IIA GP Limited

Notes to the accounts Year ended 30 June 2013

5. Other creditors

	2013 £	2012 £
Other creditors (note 8)	7,695	5
Group relief payable	163	69
	<u>7,858</u>	<u>74</u>

6. Tax charge on profit on ordinary activities

	2013 £	2012 £
The tax charge comprises		
Current tax		
UK corporation tax – group relief	(163)	(69)
Deferred tax timing difference, origination and reversal (note 8)	(416)	(222)
	<u>(579)</u>	<u>(291)</u>

Factors affecting current tax charge

The tax assessed for the year is different to that resulting from applying the rate of 23.75% (2012: 25.5%)
The differences are explained below

	2013 £	2012 £
Profit on ordinary activities before tax	<u>3,818</u>	<u>3,455</u>
Tax charge at 23.75% (2012: 25.5%) thereon	(907)	(881)
Effects of		
Movement in short-term timing differences – advance on profit share	744	812
Losses claimed/(surrendered) as group relief	164	69
Payment for group relief	<u>(164)</u>	<u>(69)</u>
Current tax charge for the year	<u>(163)</u>	<u>(69)</u>

The tax charge in future periods will be impacted by the change in the UK corporation tax rate to 23% with effect from 1 April 2013

7. Provision for liabilities and charges

	2013 £	2012 £
Deferred taxation (note 8)	<u>-</u>	<u>7,279</u>

The deferred tax balance has been moved to creditors falling due within one year as a result of applying a basis other than that of a going concern

Abingworth Bioventures IIA GP Limited

Notes to the accounts Year ended 30 June 2013

8. Deferred taxation

	2013 £	2012 £
Movement on deferred taxation balance in the year		
Opening balance	7,279	7,057
Charge to profit and loss account (note 6)	416	222
	<u>7,695</u>	<u>7,279</u>
Analysis of deferred tax balance		
Deferred tax on future known profit share	<u>7,695</u>	<u>7,279</u>
Provision for deferred tax	<u>7,695</u>	<u>7,279</u>

Deferred taxes are calculated on all timing differences using an effective rate of 23% (2012 24%)

9. Called up share capital

	2013 £	2012 £
Allotted and fully paid:		
1 ordinary share of £1	<u>1</u>	<u>1</u>

10. Reserves

	Profit and loss account £
As at 1 July 2012	12,116
Transfer to the profit and loss account for the year	<u>3,239</u>
At 30 June 2013	<u>15,355</u>

11. Reconciliation of movement in equity shareholders' funds

	£
Equity shareholders' funds as at 1 July 2012	12,117
Profit on ordinary activities after taxation	<u>3,239</u>
Equity shareholders' funds as at 30 June 2013	<u>15,356</u>

Abingworth Bioventures IIA GP Limited

Notes to the accounts Year ended 30 June 2013

12. Ultimate parent company

All of the share capital is owned by Abingworth Management Holdings Limited, a company incorporated in Great Britain and registered in England and Wales. Abingworth Management Holdings Limited represents the immediate and ultimate parent company and ultimate controlling party of Abingworth Bioventures IIA GP Limited. The smallest and largest group that prepares group accounts in which the results of the Company are included is that of Abingworth Management Holdings Limited.

Copies of the group accounts are available from the parent company's registered office at 38 Jermyn Street, London SW1Y 6DN.

13. Related party disclosures

The Company acts as general partner to Abingworth Bioventures IIA L P. During the year, income of £3,126 (2012: £3,185) was credited on account of the Company's entitlement to receive a share of net income and capital gains from Abingworth Bioventures IIA L P.

Dr Bunting, Mr Abell and Mr Leathers, directors of the Company, have made investments in Abingworth Bioventures IIA L P.

The Company has taken advantage of the exemption granted by paragraph 3(c) of Financial Reporting Standard 8, Related Party Disclosures as a wholly-owned subsidiary of Abingworth Management Holdings Limited, not to disclose related party transactions with group entities which are also 100% owned. There are no other related party transactions requiring disclosure.